Sebastian Stachowiak’s experience in the life sciences industry covers sales, marketing, business development and general management in both the UK and Europe. His roles have spanned across a number of countries, which include the UK, Ireland, Iceland and the Nordics and he holds a strong track record of establishing and growing businesses in these regions. As the General Manager of Shire UK and Ireland , Sebastian is passionate about ensuring the UK offers a sustainable future for the pharmaceutical industry, fostering an environment where new treatments can reach patients in a timely manner. Since January 2016, when he was co-opted to the ABPI Board to champion rare diseases for the industry, Sebastian has chaired the Rare Disease Strategy Group. Its aim is to deliver a consistent industry voice on key policy issues.
Rare but not forgotten: why drug appraisal methods must be updated to consider treatments for rare diseasesSubscription
The UK government needs to adapt its drug and technology appraisal methods to prevent patients with rare diseases being left out in the cold.